Goldman Sachs Group Inc Fulcrum Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $706 Billion
- Q2 2025
A detailed history of Goldman Sachs Group Inc transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,143,536 shares of FULC stock, worth $8.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,143,536
Previous 402,600
184.04%
Holding current value
$8.1 Million
Previous $1.16 Million
578.77%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding FULC
# of Institutions
131Shares Held
55.5MCall Options Held
886KPut Options Held
93.3K-
Ra Capital Management, L.P. Boston, MA10.2MShares$72.4 Million1.54% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$37.2 Million7.36% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.08MShares$36 Million1.2% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$34 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.59MShares$32.5 Million0.06% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $368M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...